Avid Bioservices Inc (CDMO)

[biopharm]

Bfiest, does it seem strange that Stephen White and John Stafford III never came back with a shareholder letter after they shook up the BOD?

I remember Acumen Pharma was one that selected Avid but I wonder why and how the undisclosed findings of the past may help prove how big PS Targeting always was.

Undisclosed...one word I think always leads to Merckly findings

______


Acumen Pharmaceuticals Lands Series A Financing

Date
4/27/2013
Company Name
Acumen Pharmaceuticals
Mailing Address
4435 North First Street Livermore, CA 94551
Company Description
Acumen Pharmaceuticals, Inc. is a biotechnology company developing disease modifying medicines and diagnostics for Alzheimerâ??s disease. Acumen Pharmaceuticals Inc. is engaged in the discovery and development of therapeutics and diagnostics related to soluble AÃ? oligomers in Alzheimerâ??s disease.
Website
http://www.acumenpharm.com
Transaction Type

Venture Equity
Transaction Amount
Undisclosed

Transaction Round
Series A
Proceeds Purposes
The capital will fund preclinical and potentially early clinical development of ACU-193, which selectively binds to and captures soluble oligomers of the amyloid-beta peptide.

M&A Terms

Venture Investor
Undisclosed

https://xconomy.com/san-francisco/2013/04/27/acumen-pharmaceuticals-lands-series-a-financing/

______

The trouble is....Merck (like many in Big Pharma) may not even realize the puzzle pieces that slowly appear and John Stafford lying to shareholders ? Not so nice

PS Targeting and the IP all are after

______


March 1, 2018

Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimerâ??s Disease Candidate

https://www.globenewswire.com/news-release/2018/03/01/1402176/0/en/Avid-Bioservices-Selected-by-Acumen-Pharmaceuticals-to-Lead-Process-Development-and-Clinical-Manufacture-of-Novel-Alzheimer-s-Disease-Candidate.html

________

Patents for William F Goure ...with big ties to Merck and Acumen (Merck has explaining to do but emails don't lie and 3D images further don't lie how well PS Targeting primes and prepares ones immune system)

Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
Patent number: 9320793
Abstract: This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
Type: Grant
Filed: December 4, 2012
Date of Patent: April 26, 2016

Assignees:
Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.

Inventors: William F. Goure, Franz F. Hefti, Renee C. Gaspar, Paul J. Shughrue, Fubao Wang, Weirong Wang, Ningyan Zhang, Wei-Qin Zhao, Alexander McCampbell, Min Xu

____

Antibodies, kit and method for detecting amyloid beta oligomers
Patent number: 9310383
Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
Type: Grant
Filed: June 3, 2015
Date of Patent: April 12, 2016

Assignees:

Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.

Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Ningyan Zhang, Wei-Qin Zhao, Min Xu
...
...
https://patents.justia.com/inventor/william-f-goure

________

Acumen Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics and diagnostics for treating Alzheimerâ??s disease and related neurodegenerative conditions. The company focuses on developing ADDL-Select antibodies that target soluble AÃ? oligomers, which are main causes in the disease process. It also uses a sensitivity assay to measure soluble AÃ? oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials. Acumen Pharmaceuticals, Inc. was founded in 1996 and is based in Livermore, California.
4435 North First Street
Suite 360
Livermore, CA 94551
United States
Founded in 1996
Phone:
925-368-8508
Fax:
925-605-3813
www.acumenpharm.com

Key Executives For Acumen Pharmaceuticals, Inc.

Mr. Daniel J. O'Connell
Chief Executive Officer, President and Director

Dr. Grant A. Krafft Ph.D.
Co-Founder, Chairman of the Board and Chief Scientific Advisor

Dr. Caleb E. Finch Ph.D.
Co-Founder and Member of Scientific Advisory Board

Dr. William F. Goure Ph.D.
Chief Operating Officer

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=8539521

________